EDRH
NRIX icon

Edmond de Rothschild Holding’s Nurix Therapeutics NRIX Stock Holding History

Edmond de Rothschild Holding’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.4M Buy
90,000
+10,000
+13% +$166K 0.02% 258
2025
Q4 		$1.52M Buy
+80,000
New +$1.15M 0.02% 268

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Edmond de Rothschild Holding's NRIX Position: Q1 2026 in Review

Edmond de Rothschild Holding increased its Nurix Therapeutics (NRIX) stake by 13% in Q1 2026, buying an estimated $166K and bringing the position to 90,000 shares worth $1.4M. The position accounts for 0.02% of the portfolio, ranked #258.

Edmond de Rothschild Holding first reported a position in NRIX in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.52M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Edmond de Rothschild Holding held 90,000 shares of Nurix Therapeutics worth $1.4M as of Q1 2026.
  • Edmond de Rothschild Holding bought 10,000 Nurix Therapeutics shares in Q1 2026, an estimated $166K.
  • Nurix Therapeutics made up 0.02% of Edmond de Rothschild Holding's portfolio in Q1 2026, its #258 holding.
  • Edmond de Rothschild Holding first reported a position in Nurix Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Edmond de Rothschild Holding's Nurix Therapeutics position peaked at $1.52M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Edmond de Rothschild Holding's 13F filing for Q1 2026, filed 13 May 2026.